Compare COHN & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | COHN | GRML |
|---|---|---|
| Founded | 1999 | N/A |
| Country | United States | United States |
| Employees | N/A | 5 |
| Industry | Investment Bankers/Brokers/Service | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.3M | 51.5M |
| IPO Year | 2003 | 2022 |
| Metric | COHN | GRML |
|---|---|---|
| Price | $11.99 | $0.29 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 20.9K | ★ 3.5M |
| Earning Date | 05-01-2026 | 05-13-2026 |
| Dividend Yield | ★ 4.35% | N/A |
| EPS Growth | ★ 5537.50 | N/A |
| EPS | ★ 0.42 | N/A |
| Revenue | ★ $275,564,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $27.98 | ★ N/A |
| Revenue Growth | ★ 246.19 | N/A |
| 52 Week Low | $8.16 | $0.27 |
| 52 Week High | $32.60 | $0.55 |
| Indicator | COHN | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 45.00 | 35.31 |
| Support Level | $10.64 | $0.27 |
| Resistance Level | $16.48 | $0.44 |
| Average True Range (ATR) | 0.53 | 0.03 |
| MACD | 0.35 | -0.00 |
| Stochastic Oscillator | 76.25 | 20.62 |
Cohen & Co Inc is a United States company that delivers financial services in fixed-income markets. It is focused on small-cap banking institutions and has grown to provide an expanding range of capital markets and asset management services. It has three business segments. The Capital Markets segment, which is the key revenue driver, consists of fixed-income sales, trading, matched book repo financing, new issue placements in corporate and securitized products, and advisory services. The Asset Management segment manages assets within collateralized debt obligations, managed accounts, joint ventures, and investment funds. The Principal Investing segment is comprised of investments to earn return rather than to support trading, matched book repo, or other Capital Markets segment activities.
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.